Last reviewed · How we verify

Vaginal prostaglandin

Ain Shams University · Phase 3 active Small molecule

Vaginal prostaglandins stimulate uterine contractions and cervical ripening to induce labor or facilitate pregnancy termination.

Vaginal prostaglandins stimulate uterine contractions and cervical ripening to induce labor or facilitate pregnancy termination. Used for Cervical ripening and labor induction, Medical abortion, Management of incomplete or missed miscarriage.

At a glance

Generic nameVaginal prostaglandin
Also known asVagiprost
SponsorAin Shams University
Drug classProstaglandin analog
TargetProstaglandin receptors (EP and FP receptors)
ModalitySmall molecule
Therapeutic areaObstetrics/Gynecology
PhasePhase 3

Mechanism of action

Prostaglandins are naturally occurring lipid mediators that bind to prostaglandin receptors on uterine smooth muscle and cervical tissue. When administered vaginally, they promote myometrial contractions and cervical softening/dilation, making them effective for labor induction, cervical ripening, and medical abortion. The vaginal route provides sustained local delivery with systemic absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: